Ключевые слова
Как цитировать
Аннотация
После хирургического лечения у значительной части больных ранним и местнораспространенным немелкоклеточным раком легкого (НМРЛ) развивается рецидив заболевания. Очевидно, что эффективная лекарственная терапия, предотвращающая развитие рецидивов при операбельном НМРЛ, по-прежнему, остро необходима. Иммунотерапия ингибиторами иммунных контрольных точек стала основой в лечении прогрессирующего НМРЛ. Неоадъювантная блокада контрольных точек хорошо переносится, не вызывая чрезмерной токсичности и увеличения послеоперационных осложнений и летальности. Клинические исследования II фазы продемонстрировали многообещающие результаты и в настоящее время ведутся проспективные исследования III фазы. Роль адъювантной иммунотерапии ингибиторами контрольных точек неясна и остается предметом изучения многочисленных проспективных исследований.
Библиографические ссылки
Siegel RL, Miller KD, Jemal A. Cancer Statistics 2017 // CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387
Goldstraw P, Chansky K, Crowley J et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification of lung cancer // J Thorac Oncol. 2016;11:39–51. doi:10.1016/j.jtho.2015.09.009
Лазутин Ю.Н., Пыльцин С.П., Харитонова А.П. Современное состояние проблемы неоадьювантной химиотерапии немелкоклеточного рака легкого (НМРЛ) // Злокачественные опухоли. 2014;3(10):22–29 [Lazutin YuN, Pyltsin SP, Kharitonova AP. Current state of the problem of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) // Zlokachestvennye opukholi. 2014;3(10):22–29 (In Russ.)].
Сагакянц А.Б. Объединенный иммунологический форум: современные направления развития фундаментальной и прикладной онкоиммунологии (Новосибирск, 2019) // Южно-Российский онкологический журнал. 2020;1(2):36–45. doi:10.37748/2687-0533-2020-1-2-5 [Sagakyants A.B. United immunological forum: current trends in the development of fundamental and applied oncoimmunology (Novosibirsk, 2019) // Yuzhno-Rossiiskii onkologicheskii zhurnal. 2020;1(2):36–45 (In Russ.)]. doi:10.37748/2687-0533-2020-1-2-5
Sharma P, Allison JP. The future of immune checkpoint therapy // Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy // Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239
Darvin P, Toor SM, Sasidharan Nair V et al. Immune checkpoint inhibitors: recent progress and potential biomarkers // Exp Mol Med. 2018;50(12). doi:10.1038/s12276-018-0191-1
Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer // N Engl J Med. 2017;377(20):1919–29. doi:10.1056/NEJMoa1709937
Mok TSK, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PDL1-expressing, locally advanced or metastatic nonsmall-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial // Lancet. 2019;393(10183):1819–30. doi:10.1016/S0140-6736(18)32409-7
Kazandjian D, Suzman DL, Blumenthal G et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy // Oncologist. 2016;21(5):634–42. doi:10.1634/theoncologist.2015-0507
Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses // Nat Rev Immunol. 2011;11:852–63. doi:10.1038/nri3108
Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity // Annu Rev Immunol 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade // Science. 1996;271:1734–6. doi:10.1126/science.271.5256.1734
Hurwitz AA, Yu TFY, Leach DR et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma // Proc Natl Acad Sci USA. 1998;95(17):10067–71. doi:10.1073/pnas.95.17.10067
Stephen Hodi F, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma // N Engl J Med. 2010;8:711–34. doi:10.1056/NEJMoa1003466
Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms // Mol Cell Biol 2005;25(21):9543–53. doi:10.1128/MCB.25.21.9543-9553.2005
Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation // J Exp Med. 2000;192(7):1027–34. doi:10.1084/jem.192.7.1027
Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion // Nat Med. 2002;8(8):793–800. doi:10.1038/nm730
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity // Curr Opin Immunol. 2012;24(2):207–12. doi:10.1016/j.coi.2011.12.009
Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced nonsmall-cell lung cancer: final results of a phase III trial // J Clin Oncol. 2012;30:2055–62. doi:10.1200/JCO.2011.39.5848
Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer // N Engl J Med. 2015;373:1627–39. doi:10.1056/NEJMoa1507643
Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer // N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1507643
Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated PD-L1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial // Lancet. 2016;387:1540–50. doi:10.1016/S0140-6736(15)01281-7
Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial // Lancet. 2016;387:1837–46. doi:10.1016/S0140-6736(16)00587-0
Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial // Lancet. 2017;389:255–65. doi:10.1016/S0140-6736(16)32517-X
Reck M, Rodriquez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer // N Engl J Med. 2016;375:1823–33. doi:10.1056/NEJMoa1606774
Gandhi L, Rodrigues-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer // N Engl J Med. 2018;378:2078–92. doi:10.1056/NEJMoa1801005
Langer CJ, Gadgeel SM, Borghaei H et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study // Lancet Oncol. 2016;17:1497–508. doi:10.1016/S1470-2045(16)30498-3
Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC // N Engl J Med. 2018;378:2280–301. doi:10.1056/NEJMoa1716948
Auperin A, Le Pechoux C, Rolland E et al. Metaanalysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer // J Clin Oncol. 2010;28:2181–90. doi:10.1200/JCO.2009.26.2543
Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer // N Engl J Med. 2017;377:1919–29. doi:10.1056/NEJMoa1709937
Owen D, Chaft J. Immunotherapy in surgically resectable non-small-cell lung cancer // J Thorac Dis. 2018;10(suppl. 3):S404–11. doi:10.21037/jtd.2017.12.93
Liu J, Blake SJ, Yong MC et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease // Cancer Discov. 2016;6:1382–99. doi:10.1158/2159-8290.CD-16-0577
Rozeman EA, Blank CU, VanAkkooi A et al. Neoadjuvant ipilimumab 1 nivolumab (IPI 1 NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses // J Clin Oncol. 2017;35(suppl. 15):9586. doi:10.1056/NEJMoa1910231
Schmid P, Park YH, Munoz-Couselo E et al. Pembrolizumab (pembro) 1 chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results fromKEYNOTE173 // J ClinOncol. 2017;35:556. doi:10.1200/JCO.2017.35.15suppl.556
Carthon BC, Wolchok JD, Yuan J et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial // Clin Cancer Res. 2010;16:2861–71. doi:10.1158/1078-0432.CCR-10-0569
Forde PM, Chaft JE, William WN et al. Neoadjuvant PD-1 blockade in reseсtable lung cancer // N Engl J Med. 2018;378:1976–86. doi:10.1056/NEJMoa1716078
Bott MJ, Yang SC, Park BJ et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer // J Thorac Cardiovasc Surg. 2019;158:269–76. doi:10.1016/j.jtcvs.2018.11.124
Rusch V, Chaft JE, Johnson B et al. Neoadjuvant atezolizumab in respectable non-small-cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3). Abstr. presented at American Society of Clinical Oncology Annual Meeting. Chicago, IL, June 3, 2018 // Journal of Clinical Oncology. 2018;36(suppl. 15):8541–8541. doi:10.1200/JCO.2018.36.15_suppl.8541
Provencio-Pulla M, Nadal-Alforja E, Cobo M et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial // Lancet Oncol. 2020;21(11):1413–1422. doi:10.1016/S1470-2045(20)30453-8
Cascone T, William WN, Weissferdt A et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical results from the NEOSTAR study // J Clin Oncol. 2019;37(15_suppl):8504 [abstract]. doi:10.1038/s41591-020-01224-2
Hellmann MD, Chaft JE, William WN et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint // Lancet Oncol. 2014;15:e42–50. doi:10.1016/S1470-2045(13)70334-6
Hellman MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden // N Engl J Med. 2018;378:2093–104. doi:10.1056/NEJMoa1801946
Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial // Lancet Oncol. 2015;16:522–30. doi:10.1016/S1470-2045(15)70271-8
Weber J, Mandala M, Del Vecchio M et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma // N Engl J Med. 2017;377:1824–35. doi:10.1056/NEJMoa1709030
Vansteenkiste J, Wauters E, Reymen B et al. Current status of immune checkpoint inhibition in early-stage NSCLC // Ann Oncol. 2019;30(8):1244-1253. doi:10.1093/annonc/mdz175
Bakos O, Lawson C, Rouleau S et al. Combining surgery and immuno-therapy: turning an immunosuppressive effect into a therapeutic oppor-tunity // J Immunother Cancer. 2018;6:86.
Patel SA, Minn AJ. Combination cancer therapy with immune check-point blockade: mechanisms and strategies // Immunity. 2018;48(3):417–433.
Broderick S. R. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung // Cancer Thorac Surg Clin. 2020;30:215–220. doi:org/10.1016/j.thorsurg.2020.01.001
Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial // Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-7
Рагулин Ю.А. Сочетание иммунотерапии и лучевой терапии при немелкоклеточном раке легкого // Онкология. 2018;7(5):90–96 doi:10.17116/onkolog2018705190 [ Ragulin YuA. The combination of immunotherapy and radiation therapy for non-small cell lung cancer // Oncologiya. 2018;7(5):90–96 (In Russ.)]. doi:10.17116/onkolog2018705190
Yang H, Jin T, Li M et al. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges // Precision Clinical Medicine. 2019:1–14. doi:10.1093/pcmedi/pbz004
Altorki NK, Borczuk AC, Saxena A et al. P2.04-92 Neoadjuvant Durvalumab with or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954) // J. of Thorac. Oncol. 2019;14(10):S746. doi:10.1016/j.jtho.2019.08.1597
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2022